157 related articles for article (PubMed ID: 14701701)
1. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma.
Lech-Maranda E; Baseggio L; Bienvenu J; Charlot C; Berger F; Rigal D; Warzocha K; Coiffier B; Salles G
Blood; 2004 May; 103(9):3529-34. PubMed ID: 14701701
[TBL] [Abstract][Full Text] [Related]
2. Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis.
Cao HY; Zou P; Zhou H
Gene; 2013 May; 519(2):288-94. PubMed ID: 23485354
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.
Giachelia M; Voso MT; Tisi MC; Martini M; Bozzoli V; Massini G; D'Aló F; Larocca LM; Leone G; Hohaus S
Leuk Lymphoma; 2012 Mar; 53(3):411-6. PubMed ID: 21902578
[TBL] [Abstract][Full Text] [Related]
4. The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma.
Berglund M; Thunberg U; Roos G; Rosenquist R; Enblad G
Blood; 2005 Jun; 105(12):4894-5; author reply 4895. PubMed ID: 15933064
[No Abstract] [Full Text] [Related]
5. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
[TBL] [Abstract][Full Text] [Related]
6. BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma.
Hu LL; Wang XX; Chen X; Chang J; Li C; Zhang Y; Yang J; Jiang W; Zhuang SM
Carcinogenesis; 2007 Aug; 28(8):1740-4. PubMed ID: 17494054
[TBL] [Abstract][Full Text] [Related]
7. The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma.
Kube D; Hua TD; Klöss M; Kulle B; Brockmöller J; Wojnowski L; Löffler M; Pfreundschuh M; Trümper L
Genes Immun; 2007 Mar; 8(2):164-7. PubMed ID: 17215862
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection.
Persico M; Capasso M; Persico E; Masarone M; Renzo Ad; Spano D; Bruno S; Iolascon A
J Hepatol; 2006 Dec; 45(6):779-85. PubMed ID: 17049666
[TBL] [Abstract][Full Text] [Related]
9. MDR1 polymorphisms have an impact on the prognosis of Chinese diffuse large B cell lymphoma patients.
Ni Y; Yin G; Xiao Z; Fan L; Wang L; Wu Y; Wu H; Qian S; Xu W; Li J; Miao K; Qiu H
Tumour Biol; 2016 Jan; 37(1):1237-44. PubMed ID: 26286835
[TBL] [Abstract][Full Text] [Related]
10. Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab.
Yri OE; Ekstrøm PO; Hilden V; Gaudernack G; Liestøl K; Smeland EB; Holte H
Leuk Lymphoma; 2013 Oct; 54(10):2205-14. PubMed ID: 23391141
[TBL] [Abstract][Full Text] [Related]
11. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma.
Lech-Maranda E; Bienvenu J; Michallet AS; Houot R; Robak T; Coiffier B; Salles G
Eur Cytokine Netw; 2006 Mar; 17(1):60-6. PubMed ID: 16613764
[TBL] [Abstract][Full Text] [Related]
12. CD38 and interleukin 6 gene polymorphism in egyptians with diffuse large B-cell lymphoma (DLBCL).
Talaat RM; Abdel-Aziz AM; El-Maadawy EA; Abdel-Bary N
Immunol Invest; 2015; 44(3):265-78. PubMed ID: 25564959
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-10 gene promoter polymorphism in Polish rheumatoid arthritis patients.
Paradowska-Gorycka A; Trefler J; Maciejewska-Stelmach J; Łacki JK
Int J Immunogenet; 2010 Aug; 37(4):225-31. PubMed ID: 20477882
[TBL] [Abstract][Full Text] [Related]
14. The association between interleukin-10 (IL-10) -592C/A, -819T/C, -1082G/A promoter polymorphisms and endometriosis.
Malutan AM; Drugan C; Walch K; Drugan T; Ciortea R; Mihu D
Arch Gynecol Obstet; 2017 Feb; 295(2):503-510. PubMed ID: 28004192
[TBL] [Abstract][Full Text] [Related]
15. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
Hiraga J; Kinoshita T; Ohno T; Mori N; Ohashi H; Fukami S; Noda A; Ichikawa A; Naoe T
Int J Hematol; 2006 Oct; 84(3):248-55. PubMed ID: 17050200
[TBL] [Abstract][Full Text] [Related]
16. Association of the interleukin-10 -592A/C, -1082G/A and -819T/C gene polymorphisms with type 2 diabetes: a meta-analysis.
Li J; Wu S; Wang MR; Wang TT; Zhu JM
Gene; 2013 Jun; 521(2):211-6. PubMed ID: 23562725
[TBL] [Abstract][Full Text] [Related]
17. Human leukocyte antigen-G polymorphisms influence the clinical outcome in diffuse large B-cell lymphoma.
Bielska M; Bojo M; Klimkiewicz-Wojciechowska G; Jesionek-Kupnicka D; Borowiec M; Kalinka-Warzocha E; Prochorec-Sobieszek M; Robak T; Warzocha K; Młynarski W; Lech-Maranda E
Genes Chromosomes Cancer; 2015 Mar; 54(3):185-93. PubMed ID: 25620080
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of interleukin-10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients.
Mtiraoui N; Ezzidi I; Kacem M; Ben Hadj Mohamed M; Chaieb M; Haj Jilani AB; Mahjoub T; Almawi WY
Diabetes Metab Res Rev; 2009 Jan; 25(1):57-63. PubMed ID: 19031431
[TBL] [Abstract][Full Text] [Related]
19. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA; Vose JM; Kruczek KR; Smith SE; Patel P; Hernandez-Ilizaliturri F; Karmali R; Rajguru S; Yang DT; Maly JJ; Blum KA; Zhao W; Vanslambrouck C; Nabhan C
Br J Haematol; 2016 Nov; 175(4):631-640. PubMed ID: 27469075
[TBL] [Abstract][Full Text] [Related]
20. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma.
Dlouhy I; Filella X; Rovira J; Magnano L; Rivas-Delgado A; Baumann T; Martínez-Trillos A; Balagué O; Martínez A; González-Farre B; Karube K; Gine E; Delgado J; Campo E; López-Guillermo A
Leuk Res; 2017 Aug; 59():20-25. PubMed ID: 28544905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
